Northwest Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Northwest Biotherapeutics generated cash of -$53,637,000, which is less than the previous year. Cash used in financing activities reached the amount of $52,758,000 last year. Net change in cash is therefore -$4,839,000.
Cash Flow
| 2014 | -54.57M | -36.35M | 85.81M |
|---|---|---|---|
| 2015 | -78.60M | -6.75M | 94.23M |
| 2016 | -55.65M | -4.93M | 38.30M |
| 2017 | -36.49M | 212K | 34.29M |
| 2018 | -34.58M | 45.40M | 7.87M |
| 2019 | -31.85M | -360K | 9.95M |
| 2020 | -32.09M | -8.14M | 52.69M |
| 2021 | -38.29M | -6.01M | 48.13M |
| 2022 | -52.77M | -2.90M | 41.96M |
| 2023 | -53.63M | -3.43M | 52.75M |
NWBO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.96M | 15.16M | 9.98M | 372K | 22.22M | 117K | 6.87M | 23.04M | 13.39M | 18.49M |
Operating activities | ||||||||||
Net income | -62.59M | -105.03M | 179.12M | -529.82M | -20.29M | -35.79M | -73.14M | -80.21M | -114.74M | -135.63M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.73M | 1.5M | 586K | 425K | -301K | 1.29M | 439K | 189K | 56K | 11K |
Stock-based compensation expense | 4.40M | 12.29M | 15.49M | 52.20M | 1.82M | 0 | 842K | 127K | 40.76M | 21.32M |
| Deferred income tax benefit | 4.40M | 12.29M | 15.49M | 52.20M | 1.82M | 0 | 842K | 127K | 40.76M | 21.32M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -4.42M | 6.84M | -597K | 2.13M | -3.71M | 3.56M | 8.20M | 18.93M | 6.96M | 24.33M |
Cash generated by operating activities | -53.63M | -52.77M | -38.29M | -32.09M | -31.85M | -34.58M | -36.49M | -55.65M | -78.60M | -54.57M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.43M | -2.90M | -6.01M | -6.61M | -360K | -193K | -8K | -4.93M | -6.75M | -33.72M |
Acquisitions Net | 0 | 0 | 0 | -1.53M | 0 | 45.59M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.43M | -2.90M | -6.01M | -8.14M | -360K | 45.40M | 212K | -4.93M | -6.75M | -36.35M |
Financing activities | ||||||||||
Common Stock Issued | 15.04M | 9.46M | 4.07M | 26.81M | 6.87M | 1.16M | 10.77M | 26.40M | 81.66M | 58.43M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 32.95M | 111K | -5.82M | -2.02M | 851K | -18.28M | 8.72M | -1.78M | 4.99M | -25K |
Cash used in financing activities | 52.75M | 41.96M | 48.13M | 52.69M | 9.95M | 7.87M | 34.29M | 38.30M | 94.23M | 85.81M |
Net Change In Cash | -4.83M | -8.20M | 5.18M | 9.61M | -21.85M | 22.10M | -6.75M | -16.17M | 8.42M | -5.10M |
Cash at end of period | 2.12M | 6.96M | 15.16M | 9.98M | 372K | 22.22M | 117K | 6.87M | 21.81M | 13.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |